An Industry Perspective: Future of Anti-Amyloid Trials

Trial outcomes across a spectrum of investigational therapies targeting the “amyloid cascade” for modifying the course of Alzheimer’s disease have generated controversy and cast doubts about the potential for success of the amyloid pathway as a target. The use of the term “amyloid cascade” as a singular molecular target is misleading. Given the differentiated molecular and cellular mechanisms interacting in amyloid-β homeostasis and the non-linear, dynamic nature of the biochemical process, the terms “amyloid pathway” or “amyloid cycle” have been proposed.